A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-Tumor Activity of Subcutaneous Tarlatamab in Subjects with Extensive Stage Small Cell Lung Cancer (DeLLphi-308)

AMG 757 20230298 (DeLLphi-308)

Comprehensive Cancer Center Mainfranken

Lungentumoren

Kleinzelliges Bronchialkarzinom (SCLC)

Phase I/IB

Herr Dr. Horst-Dieter Hummel

Frau Dr. Maria-Elisabeth Goebeler

Interdisziplinäres Studienzentrum mit Early Clinical Trial Unit

Universitätsklinikum Würzburg

Zweitlinie

Therapeutisch